Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey\n\nPosted by Defense World Staff on Jun 6th, 2025\n\nBright Minds Biosciences (NASDAQ:DRUG – Get Free Report) and SCYNEXIS (NASDAQ:SCYX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.\n\nInsider and Institutional Ownership\n\n40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.\n\nEarnings & Valuation\n\nThis table compares Bright Minds Biosciences and SCYNEXIS’s revenue, earnings per share and valuation.\n\n\nGross Revenue\nPrice/Sales Ratio\nNet Income\nEarnings Per Share\nPrice/Earnings Ratio\n\nBright Minds Biosciences\nN/A\nN/A\n-$2.06 million\n($0.36)\n-77.25\n\nSCYNEXIS\n$2.63 million\n13.14\n$67.04 million\n($0.56)\n-1.58\n\nSCYNEXIS has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.\n\nAnalyst Ratings\n\nThis is a summary of recent ratings and price targets for Bright Minds Biosciences and SCYNEXIS, as provided by MarketBeat.\n\n\nSell Ratings\nHold Ratings\nBuy Ratings\nStrong Buy Ratings\nRating Score\n\nBright Minds Biosciences\n0\n0\n6\n2\n3.25\n\nSCYNEXIS\n0\n0\n0\n0\n0.00\n\nBright Minds Biosciences currently has a consensus target price of $83.25, indicating a potential upside of 199.35%. Given Bright Minds Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Bright Minds Biosciences is more favorable than SCYNEXIS.\n\nRisk & Volatility\n\nBright Minds Biosciences has a beta of -5.75, indicating that its share price is 675% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.\n\nProfitability\n\nThis table compares Bright Minds Biosciences and SCYNEXIS’s net margins, return on equity and return on assets.\n\n\nNet Margins\nReturn on Equity\nReturn on Assets\n\nBright Minds Biosciences\nN/A\n-5.85%\n-5.68%\n\nSCYNEXIS\n-425.41%\n-66.21%\n-38.84%\n\nSummary\n\nBright Minds Biosciences beats SCYNEXIS on 9 of the 14 factors compared between the two stocks.\n\nAbout Bright Minds Biosciences\n\n(Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.)\n\nAbout SCYNEXIS\n\n(SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.)\n\nReceive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey

The article compares Bright Minds Biosciences and SCYNEXIS based on financial metrics, institutional ownership, analyst ratings, and risk profiles. Bright Minds is deemed superior on 9 of 14 factors, including lower volatility, stronger analyst ratings, and better profitability metrics, though SCYNEXIS outperforms in revenue and earnings.